Mindbloom
Mindbloom is a U.S. telehealth platform founded in 2018 that provides at-home, clinician-prescribed ketamine-assisted therapy for adults with anxiety, depression, PTSD, and related mental health conditions across 36 states, supported by an AI-powered mobile app and a subscription-based cash-pay model with insurance reimbursement optionality.
- Company typePrivate
- Founded2018
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Mindbloom does
Mindbloom is a U.S.-based, venture capital-backed telehealth platform founded in 2018 by Dylan Beynon that provides at-home, clinician-prescribed ketamine-assisted therapy for adults with anxiety, depression, PTSD, prolonged grief disorder, burnout, and other mental health conditions. The platform pairs individuals with licensed psychiatric clinicians (operating through a network of affiliated PC medical entities across five jurisdictions) who conduct telehealth evaluations and prescribe personalized ketamine treatment plans using either sublingual tablets or subcutaneous injectables. At-home administration is enabled by a standardized Bloombox kit containing a digital blood pressure monitor, AI-powered mobile app features (BloomBuddy, Voice Journaling) for session preparation and integration, required peer treatment monitoring, and guide coaching via 1:1 messaging and group integration circles.
The underlying technology stack is a HIPAA-style compliant telehealth platform with AI-augmented clinical documentation (integrations with OpenAI, Fireflies.ai, Zoom AI, Upheal, and Intercom Fin), plus applied machine learning on real-world treatment outcomes data. Mindbloom claims the two largest published peer-reviewed studies of ketamine therapy to date, including a 2022 Journal of Affective Disorders publication and a 13,963-patient sleep outcomes analysis, and operates in 36 states reaching approximately 84% of the U.S. population with 800,000+ therapy sessions facilitated cumulatively.
The business model is a direct-to-consumer, cash-pay subscription program priced at approximately 75% less than IV ketamine clinic alternatives, with out-of-network insurance reimbursement supported via superbill submission across Anthem, Aetna, United Healthcare, Cigna, Kaiser, and Blue Cross Blue Shield, and HSA/FSA payment accepted. Customer acquisition relies on content marketing, SEO, organic social media, podcast appearances by leadership, earned media, and an affiliate program. Mindbloom has raised hundreds of millions of dollars from Tier 1 VCs (Founders Fund, Kleiner Perkins, 8VC, Delphi VC, among others) across disclosed rounds in 2020 and 2021, employs 400+ personnel ('Bloomineers') on a remote-first basis, and faces an active wrongful death lawsuit (Phillip Ward) related to alleged screening failures that represents a material regulatory and reputational overhang.
Mindbloom firmographics
Firmographics- Name
- Mindbloom
- Legal name
- Mindbloom, Inc.
- Website
- https://mindbloom.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Mindbloom is a U.S. telehealth platform founded in 2018 that provides at-home, clinician-prescribed ketamine-assisted therapy for adults with anxiety, depression, PTSD, and related mental health conditions across 36 states, supported by an AI-powered mobile app and a subscription-based cash-pay model with insurance reimbursement optionality.
- Ownership category
- akta.pro rank
Mindbloom industry classification
Industry- Product category
- Telehealth Mental Health Services
- NAICS
- Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Mental Health Practitioners (except Physicians) (621330)
- SIC
- Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Psychiatry & Medication Management Platforms (HLALAEAB)
- akta.pro secondary industries
- General Mental Health Therapy Platforms (Talk Therapy) (HLALAEAA), Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)
Keywords
Where Mindbloom is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mindbloom business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Ketamine Therapy Program Subscriptions: Recurring subscription-based access to at-home ketamine therapy programs including clinician consultations, guide support, medication, and app-based tools. Clients can seek insurance reimbursement via superbill submission for out-of-network benefits. HSA/FSA funds also accepted.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | At-home ketamine therapy program with clinician support, guide coaching, and medication |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
Mindbloom product offering
Product offeringCore offering
Mindbloom provides at-home, clinician-prescribed ketamine therapy via a telehealth platform for adults with anxiety, depression, PTSD, and related mental health conditions. The program pairs clients with licensed psychiatric clinicians who evaluate, prescribe, and monitor treatment using sublingual tablets or subcutaneous injectables, supported by AI-powered mobile app tools, guide coaching, and structured integration content. Treatment is delivered in 36 U.S. states with insurance reimbursement support via superbill and HSA/FSA payment acceptance.
Product overview
Mindbloom is a telehealth platform offering at-home ketamine-assisted therapy for mental health conditions. The core offering consists of a unified therapy program that provides clinician-guided ketamine treatment (available as sublingual Tablets or subcutaneous Injectables) paired with licensed psychiatric clinicians, AI-powered mobile app features (BloomBuddy), guide coaching, peer treatment monitoring, and structured integration support. The platform spans condition-specific programs for anxiety, depression, PTSD, burnout, grief, and other focus areas, and has facilitated over 800,000 sessions across 36 states. The company publishes peer-reviewed clinical outcomes and operates the Mindbloom Shop for merchandise. Insurance reimbursement support is available through superbill generation for out-of-network benefits.
Differentiator
Problem solved
Functional benefit
Products and services
- Mindbloom At-Home Ketamine Therapy Program Telehealth-based at-home ketamine-assisted therapy program pairing individuals with licensed clinicians for diagnosis and treatment of anxiety, depression, PTSD, and other mental health conditions. Includes medical evaluation, personalized treatment plans, guided sessions, and ongoing clinician monitoring.
- Mindbloom Tablets (Sublingual Ketamine) Sublingual ketamine tablets administered under the tongue or between cheek and gums for 7 minutes, then spit out. Part of the at-home ketamine therapy program offering for adults with treatment-resistant mental health conditions.
- Mindbloom Injectables (Subcutaneous Ketamine) Subcutaneous ketamine injection treatment offering as an alternative to sublingual tablets. Marketed as a premium at-home form factor, with reported 81% client preference over tablets.
- Anxiety Program Ketamine therapy program targeting anxiety symptoms, with outcomes data showing GAD-7 response and remission rates from peer-reviewed research.
- Depression Program Ketamine therapy program targeting depression symptoms, with outcomes data showing PHQ-9 response and remission rates.
- PTSD Program Ketamine therapy program targeting PTSD symptoms, including PCL-5 response and remission rates from Mindbloom's outcomes research.
- Mindbloom 101 Program Introductory program for new clients covering foundational knowledge about psychedelic therapy and Mindbloom's approach.
- Telehealth Eligibility and Onboarding Self-service eligibility quiz and onboarding via welcome.mindbloom.com with telehealth clinical evaluation by licensed psychiatric clinicians who prescribe personalized ketamine treatment plans via video consultation.
- Mindbloom Shop E-commerce store for Mindbloom merchandise and products.
Quantifiable outcome
- 89% of clients report improvement in depression and anxiety symptoms after 4 sessions
- +7 more outcomes
Companies that use Mindbloom
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Mindbloom technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability7 records
Feature5 records
Mindbloom partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core, major and supporting.
- AnthemcoreInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments, covering over 50% of program costs for eligible members.
- AetnacoreInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.
- United HealthcarecoreInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.
- CignacoreInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.
- KaisercoreInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.
- Blue Cross Blue ShieldcoreInsurance provider through which clients may receive reimbursement for Mindbloom ketamine therapy treatments.
- Cleveland ClinicmajorResearch collaboration with Cleveland Clinic psychiatry department on peer-reviewed ketamine therapy study published in Journal of Affective Disorders. Co-authors from Cleveland Clinic contributed to landmark outcomes research.
- UCSFmajorResearch collaboration with UCSF psychiatry department on peer-reviewed ketamine therapy study published in Journal of Affective Disorders.
- NYUmajorResearch collaboration with NYU Langone Health on peer-reviewed ketamine therapy study published in Journal of Affective Disorders.
- Houston MethodistmajorResearch collaboration with Houston Methodist on peer-reviewed ketamine therapy study published in Journal of Affective Disorders.
- OpenAIcoreIntegration of OpenAI technology into BloomBuddy tool for transcription and clinical documentation support within the Mindbloom app.
- Fireflies.aisupportingAI tool used to transcribe video meetings for purposes of creating clinical notes and quality assurance.
- UphealsupportingAI tool for clinical documentation, supporting clinician workflow and session record-keeping.
- ZoomsupportingVideo conferencing platform with AI transcription and analysis capabilities for clinical documentation and protocol compliance.
- IntercomsupportingCustomer support chatbot (Fin AI-Powered Chatbot) addressing customer inquiries on the website.
Scale indicators10 records
Recent moves6 records
Expansion highlights7 records
Mindbloom competitors and assessment
Company assessmentDirect peers
- Nue Life Health: Nue Life is a direct at-home ketamine therapy competitor offering telehealth-led treatment programs with preparation and integration support, closely matching Mindbloom's core model and customer profile.
- Innerwell: Innerwell is a direct at-home ketamine therapy provider offering psychiatrist-led programs with integration support, targeting similar treatment-resistant depression and anxiety populations as Mindbloom.
- Field Trip Health: Field Trip Health operated a national network of ketamine therapy clinics and was widely cited alongside Mindbloom as a key market player; it has since restructured and is pivoting toward at-home and virtual models that overlap directly with Mindbloom.
- Better U: Better U is a direct at-home ketamine therapy provider operating a virtual model with clinician-prescribed treatment, closely paralleling Mindbloom's telehealth-led DTC approach.
- Wondermed: Wondermed is an at-home ketamine therapy provider with clinician-led programs and integration support, targeting similar patient demographics and competing in the same direct-to-consumer telehealth channel as Mindbloom.
Broad incumbents
- Hims & Hers Health: Hims & Hers is a large incumbent telehealth platform that has expanded into mental health prescribing (including anxiety and depression). It offers overlapping capabilities as a broader consumer health brand, but does not specialize in ketamine therapy.
- Cerebral: Cerebral is a digital mental health platform offering online psychiatric evaluation and prescription treatment for anxiety and depression, overlapping with Mindbloom's behavioral health prescribing category at a broader scale.
- Spravato (Johnson & Johnson): Spravato is the FDA-approved esketamine nasal spray for treatment-resistant depression marketed by J&J. It is the principal FDA-approved ketamine-based therapy and competes with Mindbloom for the same patient population, but requires in-clinic administration under REMS.
- Talkspace: Talkspace is a large incumbent online therapy and psychiatry platform serving similar behavioral health consumers with both therapy and medication management, overlapping in target market but differing in modality (talk therapy vs. ketamine).
Emerging players
- Compass Pathways: Compass Pathways is a clinical-stage psychedelic therapy company developing psilocybin treatment for treatment-resistant depression. It targets the same underlying patient need as Mindbloom and represents the next generation of FDA-approved psychedelic alternatives.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Mindbloom social profiles
Digital presenceMindbloom compliance and trust
Trust signalCompliance2 records
Mindbloom financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mindbloom leadership team
Management profileNumber of profiles
Profiles9 records
Mindbloom subsidiaries and ownership
Company hierarchySubsidiaries5 records
Mindbloom funding detail
Funding detailFunding overview
Funding rounds4 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mindbloom M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mindbloom
What does Mindbloom do?
Mindbloom provides at-home, clinician-prescribed ketamine therapy via a telehealth platform for adults with anxiety, depression, PTSD, and related mental health conditions. The program pairs clients with licensed psychiatric clinicians who evaluate, prescribe, and monitor treatment using sublingual tablets or subcutaneous injectables, supported by AI-powered mobile app tools, guide coaching, and structured integration content. Treatment is delivered in 36 U.S. states with insurance reimbursement support via superbill and HSA/FSA payment acceptance.
Is Mindbloom a public or private company?
Mindbloom is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mindbloom founded?
Mindbloom was founded in 2018. It employs 1 to 10 people.
Where is Mindbloom based?
Mindbloom is headquartered in New York, United States, in the North America region.
How does Mindbloom make money?
One revenue line is on record: ketamine Therapy Program Subscriptions.
Who are Mindbloom's main competitors?
Direct peers on record are Nue Life Health, Innerwell, Field Trip Health, Better U and Wondermed. Broad incumbents are Hims & Hers Health, Cerebral, Spravato (Johnson & Johnson) and Talkspace. Compass Pathways is listed as an emerging player.
Does Mindbloom have an API?
No public API is recorded for Mindbloom.
What industry is Mindbloom in?
Mindbloom's product category is Telehealth Mental Health Services. Its primary akta.pro industry code is HLALAEAB, Psychiatry & Medication Management Platforms, with a secondary code of HLALAEAA, General Mental Health Therapy Platforms (Talk Therapy). Its NAICS code is 621112 and its SIC code is 8000.